Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Allergic rhinitis drugs industry 3600 synopsis, 2018 - 2032
2.2 Business trends
2.2.1 Disease type trends
2.2.2 Treatment type trends
2.2.3 Drug type trends
2.2.4 Route of administration trends
2.2.5 Distribution channel trends
2.2.6 Regional trends
Chapter 3 Allergic Rhinitis Drugs Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 – 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising awareness about the allergic reactions and available treatment modes
3.3.1.2 Increasing prevalence of allergic rhinitis
3.3.1.3 Technological advancements in the field of allergy diagnosis and treatment
3.3.1.4 Growing pollution levels coupled with rise in respiratory disorders
3.3.2 Industry pitfalls & challenges
3.3.2.1 Side effects associated allergic rhinitis treatments
3.3.2.2 Similarity of symptoms with other diseases
3.4 Growth potential analysis
3.4.1 By disease type
3.4.2 By treatment type
3.4.3 By drug type
3.4.4 By route of administration
3.4.5 By distribution channel
3.5 COVID-19 impact analysis
3.6 Technology landscape
3.7 Drug approval scenario
3.8 Allergic Rhinitis: Causes and treatment scenario
3.9 Product pipeline analysis
3.10 List of drugs used in allergic rhinitis medication
3.11 Key market trends
3.12 Epidemiology scenario
3.13 Regulatory landscape
3.13.1 U.S.
3.13.2 Europe
3.14 Gap analysis
3.15 Reimbursement scenario
3.16 Porter’s analysis
3.17 PESTEL analysis
Chapter 4 Competitive Landscape, 2021
4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Competitive analysis of major market players
4.4 Competitive Positioning matrix
4.5 Strategy dashboard, 2021
Chapter 5 Allergic Rhinitis Drugs Market, By Disease Type
5.1 Key segment trends
5.2 Seasonal allergic rhinitis
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Perennial allergic rhinitis
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Occupational allergic rhinitis
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Allergic Rhinitis Drugs Market, By Treatment Type
6.1 Key segment trends
6.2 Antihistamines
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Immunotherapy
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.2 SCIT
6.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.3 SLIT
6.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Corticosteroids
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Decongestants
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Others
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Allergic Rhinitis Drugs Market, By Drug Type
7.1 Key segment trends
7.2 Prescription
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 OTC
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Allergic Rhinitis Drugs Market, By Route of Administration
8.1 Key segment trends
8.2 Oral
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Nasal
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Intraocular
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.5 Intravenous
8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Allergic Rhinitis Drugs Market, By Distribution Channel
9.1 Key segment trends
9.2 Retail pharmacies
9.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
9.3 Hospital pharmacies
9.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
9.4 Online channel
9.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 10 Allergic Rhinitis Drugs Market, By Region
10.1 Key regional trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
Chapter 11 Company Profiles
11.1 Merck & Co.
11.2 Teva Pharmaceutical Industries Ltd.
11.3 GlaxoSmithKline PLC
11.4 Boehringer Ingelheim
11.5 Stallergenes Greer
11.6 Unichem Laboratories
11.7 Sanofi S.A.
11.8 Johnson & Johnson
11.9 Alcon (Novartis AG)
11.10 Mylan NV
11.11 Meda AB
11.12 Allergy Therapeutics PLC
11.13 Glenmark Pharmaceuticals Ltd
11.14 ALK-Abelló A/S
11.15 Bayer AG
11.16 Adamis Pharmaceuticals
11.17 Dr Reddy’s Laboratories
11.18 Sun Pharmaceuticals
